Income Statement (Annual)

BSFT / BroadSoft, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016
Sales Revenue Net
  Licenses Revenue 37,942 53,302 77,289 89,750 94,408 103,311 119,808 129,313
  License And Maintenance Revenue - 33,743 42,462 58,249 69,357 92,492 112,836 146,615
  Technology Services Revenue - 8,578 18,313 16,843 14,728 21,054 46,199 65,034
  Sales Revenue Net 68,887 95,623 138,064 164,842 178,493 216,857 278,843 340,962
Cost Of Goods And Services Sold
  License Costs 4,432 5,341 5,475 8,643 9,241 9,667 10,231 7,585
  Cost Of Services Licenses And Maintenance Agreements - 7,691 10,419 14,831 21,368 33,232 38,602 46,717
  Technology Services Costs - 7,010 8,478 9,012 10,771 14,814 28,925 36,875
  Cost Of Goods And Services Sold 17,374 20,042 24,974 32,486 41,380 57,713 77,758 91,177
Gross Profit 51,513 75,581 113,090 132,356 137,113 159,144 201,085 249,785
Operating Expenses
  Selling And Marketing Expense 28,534 31,818 38,376 47,911 62,174 69,681 83,806 107,142
  Research And Development Expense 16,625 19,616 27,744 36,178 49,696 49,515 60,749 77,202
  General And Administrative Expense 11,405 14,103 19,534 22,863 32,580 32,729 41,287 49,934
  Operating Expenses 56,564 65,537 85,654 106,952 144,450 151,925 185,842 234,278
Operating Income Loss -5,051 10,044 27,436 25,404 -7,337 7,219 15,243 15,507
Nonoperating Income Expense
  Interest Expense 1,398 757 3,592 6,925 7,400 7,706 10,656 15,756
  Interest Income Other - - - - - 529 1,270 2,680
  Other Nonoperating Income Expense -110 -174 - - - - - -
  Nonoperating Income Expense -1,469 -879 -3,314 -6,470 -6,946 -8,477 -15,100 -13,231
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments -6,520 9,165 24,122 18,934 -14,283 -1,258 143 2,276
Income Tax Expense Benefit 1,333 1,169 -8,175 6,858 -5,409 -2,270 -36 1,460
Profit Loss -7,853 7,996 32,297 12,076 -8,874 1,012 179 -
Earnings Per Share
  Earnings Per Share Basic And Diluted - - - - - - - -
Weighted Average Number Of Shares Outstanding
  Weighted Average Number Of Share Outstanding Basic And Diluted - - - - - - - -
Share Based Compensation
  Share Based Compensation 3,629 3,008 7,201 15,022 41,684 29,628 40,444 51,507

Peers - Prepackaged Software (7372)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 11133B409